APP
MRSN

Alpha Paradigm Partners’s Mersana Therapeutics MRSN Stock Holding History

Alpha Paradigm Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$343K Buy
+2,343
New +$396K 0.14% 224

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alpha Paradigm Partners's MRSN Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Mersana Therapeutics (MRSN) in Q4 2022: 2,343 shares worth $343K. The stake represents 0.14% of the portfolio and ranks #224 among its holdings.

152 funds tracked by Wall St. Rank hold MRSN as of Q4 2022.

  • Alpha Paradigm Partners held 2,343 shares of Mersana Therapeutics worth $343K as of Q4 2022.
  • Mersana Therapeutics was a new Alpha Paradigm Partners position in Q4 2022.
  • Mersana Therapeutics made up 0.14% of Alpha Paradigm Partners's portfolio in Q4 2022, its #224 holding.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.